Esperion stock holds Buy rating, $16 target from H.C. Wainwright
H.C. Wainwright maintained a positive stance on Esperion Therapeutics (NASDAQ:ESPR) shares, reaffirming a Buy rating and a price target of $16.00. According to InvestingPro data, analyst targets for ...
Esperion stock target cut to $4 by JMP Securities
JMP Securities adjusted its price target for Esperion Therapeutics (NASDAQ:ESPR) shares, lowering it to $4.00 from the previous $7.00. Currently trading at $1.86, the stock sits well below analyst ...
Esperion price target lowered to $4 from $7 at JMP Securities
JMP Securities lowered the firm’s price target on Esperion (ESPR) to $4 from $7 and keeps an Outperform rating on the shares. JMP updated its ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Enanta Pharmaceuticals (ENTA) and Esperion (ESPR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report), Enanta Pharmaceuticals ...
Morningstar27d
Esperion Therapeutics Inc ESPR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Investing28d
Esperion stock falls on higher operating expense forecast
Investing.com -- Shares of Esperion (NASDAQ:ESPR) Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December 31, ...
Investing28d
Esperion stock falls on higher operating expense forecast
Investing.com -- Shares of Esperion (NASDAQ:ESPR) Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December ...